GlassScriptPhysician profile
Puneet Bedi
NPI 1881838324
$3,347.49
in general payments reported to CMS, 2019-2025
18 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $162 · 2021: $601 · 2022: $726 · 2023: $851 · 2024: $202 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.29 |
| Education | $230.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $517.14 | 2021-2024 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $432.25 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $358.01 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $347.74 | 2019-2023 | Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $273.85 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $252.16 | 2019-2023 | Ultomiris |
| Travere Therapeutics, INC. | $229.71 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $208.99 | 2021-2024 | Jynarque |
| Amgen INC. | $188.59 | 2019-2025 | Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.05 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $83.01 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $82.28 | 2019 | |
| Biomerieux INC | $76.97 | 2019 | |
| Glaxosmithkline, LLC. | $63.67 | 2022-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $42.75 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.85 | 2023 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Renalytix Ai, INC. | $21.86 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Bedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.